Targeting lentiviral vectors for cancer immunotherapy. Arce F, Breckpot K, Collins M, Escors D. Curr Cancer Ther Rev. 2011 Nov;7(4):248-260.

F. Arce, Karine Breckpot, M. Collins, D. Escors

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Delivery of tumour-associated antigens (TAA) in a way that induces effective, specific immunity is a challenge in anti-cancer vaccine design. Circumventing tumour-induced tolerogenic mechanisms in vivo is also critical for effective immunotherapy. Effective immune responses are induced by professional antigen presenting cells, in particular dendritic cells (DC). This requires presentation of the antigen to both CD4(+) and CD8(+) T cells in the context of strong co-stimulatory signals. Lentiviral vectors have been tested as vehicles, for both ex vivo and in vivo delivery of TAA and/or activation signals to DC, and have been demonstrated to induce potent T cell mediated immune responses that can control tumour growth. This review will focus on the use of lentiviral vectors for in vivo gene delivery to DC, introducing strategies to target DC, either targeting cell entry or gene expression to improve safety of the lentiviral vaccine or targeting dendritic cell activation pathways to enhance performance of the lentiviral vaccine. In conclusion, this review highlights the potential of lentiviral vectors as a generally applicable 'off-the-shelf' anti-cancer immunotherapeutic.
Original languageEnglish
Pages (from-to)248-260
Number of pages13
JournalCurr Cancer Ther Rev.
Volume4
Issue number7
Publication statusPublished - Nov 2011

Keywords

  • lentiviral vector
  • dendritic cell
  • T cell
  • cancer

Fingerprint Dive into the research topics of 'Targeting lentiviral vectors for cancer immunotherapy. Arce F, Breckpot K, Collins M, Escors D. Curr Cancer Ther Rev. 2011 Nov;7(4):248-260.'. Together they form a unique fingerprint.

Cite this